Why Did Ken Griffin Buy Sweetgreen Stock?
In Q1, Ken Griffin’s Citadel Advisors purchased nearly 1.3 million…
Sell
44
VKTX Quote, Financials, Valuation and Earnings
Last price:
$28.97
Seasonality move
:
1.1%
Day range:
$28.72 - $30.17
52-week range:
$18.92 - $81.73
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.86x
Volume:
5.2M
Avg. volume:
3.1M
1-year change:
-45.1%
Market cap:
$3.3B
Revenue:
--
EPS (TTM):
-$1.15
Analysts' Opinion
-
Consensus RatingViking Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $90.26, Viking Therapeutics has an estimated upside of 209.76% from its current price of $28.95.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $30.00 representing 100% downside risk from its current price of $28.95.
Fair Value
-
According to the consensus of 12 analysts, Viking Therapeutics has 209.76% upside to fair value with a price target of $90.26 per share.
VKTX vs. S&P 500
-
Over the past 5 trading days, Viking Therapeutics has overperformed the S&P 500 by 7.7% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Viking Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Viking Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Viking Therapeutics reported revenues of --.
Earnings Growth
-
Viking Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Viking Therapeutics reported earnings per share of -$0.41.
Enterprise value:
2.4B
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-18.07x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$74.6M | -$114.4M | -$172.3M | -$34.1M | -$55.5M | |
| EBITDA | -$74.4M | -$114.1M | -$171.9M | -$34M | -$55.4M | |
| Diluted EPS | -$0.95 | -$0.93 | -$1.15 | -$0.26 | -$0.41 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $249.9M | $193.3M | $149.5M | $966.3M | $866M | |
| Total Assets | $250.1M | $195M | $150.9M | $967.5M | $867M | |
| Current Liabilities | $12.9M | $11.3M | $15.6M | $32.8M | $19.6M | |
| Total Liabilities | $12.9M | $12.8M | $16.8M | $33.6M | $20.1M | |
| Total Equity | $237.2M | $182.3M | $134.1M | $933.9M | $846.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$62.5M | -$54.9M | -$134M | -$6.1M | -$52.3M | |
| Cash From Investing | $55.3M | -$641.1M | -$30.3M | -$459.8M | $63.2M | |
| Cash From Financing | $13.4M | $873.2M | $6.8M | $606M | $349K | |
| Free Cash Flow | -$62.5M | -$54.9M | -- | -$6.1M | -- | |
VKTX
Sector
Market Cap
$3.3B
$34.2M
Price % of 52-Week High
35.65%
47.37%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-48.32%
-35.99%
Beta (5-Year)
0.648
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$27.53
200-day SMA
Sell
Level
$42.73
Bollinger Bands (100)
Buy
Level
25.06 - 31.54
Chaikin Money Flow
Buy
Level
7.9M
20-day SMA
Buy
Level
$27.50
Relative Strength Index (RSI14)
Buy
Level
58.05
ADX Line
Buy
Level
10.74
Williams %R
Sell
Level
-17.1149
50-day SMA
Buy
Level
$26.23
MACD (12, 26)
Buy
Level
0.33
25-day Aroon Oscillator
Buy
Level
20
On Balance Volume
Neutral
Level
372.1M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Stock Forecast FAQ
In the current month, VKTX has received 10 Buy ratings 2 Hold ratings, and 0 Sell ratings. The VKTX average analyst price target in the past 3 months is $90.26.
-
Where Will Viking Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Viking Therapeutics share price will rise to $90.26 per share over the next 12 months.
-
What Do Analysts Say About Viking Therapeutics?
Analysts are divided on their view about Viking Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Viking Therapeutics is a Sell and believe this share price will drop from its current level to $30.00.
-
What Is Viking Therapeutics's Price Target?
The price target for Viking Therapeutics over the next 1-year time period is forecast to be $90.26 according to 12 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is VKTX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Viking Therapeutics is a Buy. 10 of 12 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of VKTX?
You can purchase shares of Viking Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Viking Therapeutics shares.
-
What Is The Viking Therapeutics Share Price Today?
Viking Therapeutics was last trading at $28.97 per share. This represents the most recent stock quote for Viking Therapeutics. Yesterday, Viking Therapeutics closed at $28.95 per share.
-
How To Buy Viking Therapeutics Stock Online?
In order to purchase Viking Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Planet Labs’ Stock Go Next?
On 4 June 2025 Planet reported Q1 FY 2026 revenue of $66.3 million, up 10% year over…
Where Will VICI Properties Be in 5 Years?
VICI Properties (NYSE:VICI) is a real estate investment trust focused…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 40x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 49x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Buy
73
OKLO alert for Jun 12
Oklo [OKLO] is up 29.48% over the past day.
Buy
87
SMR alert for Jun 12
NuScale Power [SMR] is up 20.55% over the past day.
Buy
53
PLAY alert for Jun 12
Dave & Buster's Entertainment [PLAY] is up 17.78% over the past day.
